12:00 AM
 | 
Jan 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LX1031: Phase II started

Lexicon began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 250 and 1,000 mg of oral LX1031 given 4 times daily for 4 weeks in up to 150 patients...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >